Regaining compliance with Nasdaq's listing requirements is a significant positive development for NeuroSense Therapeutics. It removes the immediate risk of delisting, which can have negative implications for stock liquidity and investor perception. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.